Question 11 : What percentage of patients presenting with renal mass have a concomitant tumor thrombus :
a) 4-10
b) 2-5
c) < 2
d) 30
Answer : 4-10%
Question 12 : Nephrectomy is to be done in patients of metastatic RCC who:
a) Have ECOG PS 0-1
b) Don’t have brain metastasis
c) Both of the above
d) Nephrectomy is not done in metastatic RCC as there is no survival advantage and TKIs are the mainstay of treatment
Answer : both of the above
Question 13 : Which of the following is not a part of MSKKC score used in metastatic RCC:
a) Karnofsky PS
b) Neutrophil count
c) Serum hemoglobin
d) Time from initial RCC diagnosis to start of therapy
Answer : Neutrophil count
Question 14 : Which of the following is not a part of Heng score used in metastatic RCC:
a) Karnofsky PS
b) Corrected serum calcium
c) Neutrophil count
d) Serum lactate dehydrogenase
Answer : Serum lactate dehydrogenase
Question 15 : Which of the following is not included in non-muscle invasive bladder cancer :
a) Tumors that haven’t penetrated the epithelial basement membrane
b) Tumors that invade the submucosa but not the underlying muscle
c) Carcinoma in situ (CIS)
d) Tumors confined within the underlying muscle but not penetrating beyond it
Answer : Tumors confined within the underlying muscle but not penetrating beyond it
Question 16 : Activating point mutations in fibroblast growth factor receptor 3 (FGFR 3) are present most commonly in which stage of urinary bladder :
a) Ta
b) T1 NMIBC
c) T1 MIBC
d) These mutations are characteristically absent in urinary bladder cancers
Answer : Ta
Question 17 : Aristolochic acid present in Aristolochia plants is the etiologic agent for Blakan nephropathy. These patients have increased incidence of :
a) Upper urinary tract tumors
b) Lower urinary tract tumors
c) Bladder dome cancers
d) Urethral squamous cell carcinoma
Answer : Upper urinary tract tumors
Question 18 : Which of the following tests is/are indicated in the surveillance of low-risk NMIBC post treatment :
a) Urine cytology
b) Urine biomarker panel
c) Cystoscopy
d) None of the above
Answer : none of the above
Question 19 : Which is the preferred imaging modality for the study of upper urinary tract cancers :
a) CT urogram
b) MRI urogram
c) Intravenous pyelogram
d) PET-CT scan
Answer : CT urogram